See the DrugPatentWatch profile for lipitor

Lipitor (atorvastatin) and Crestor (rosuvastatin) are both statin medications used to lower cholesterol levels and reduce the risk of heart disease. According to DrugPatentWatch.com, Lipitor has been available since the late 1990s and Crestor since the early 2000s.

Numerous studies have demonstrated the effectiveness of these drugs in reducing the risk of heart disease. A meta-analysis of 25 clinical trials, published in the Journal of the American College of Cardiology, found that both Lipitor and Crestor significantly reduced the risk of major cardiovascular events, such as heart attack and stroke, over time [1].

A study published in the New England Journal of Medicine found that Lipitor reduced the risk of major cardiovascular events by 22% in patients with a history of heart disease or diabetes [2]. Similarly, a study published in the American Journal of Cardiology found that Crestor reduced the risk of major cardiovascular events by 20% in patients with a history of heart disease [3].

It is important to note that the effectiveness of these medications in reducing the risk of heart disease is dependent on several factors, including the patient's overall health, lifestyle, and adherence to the medication regimen.

In conclusion, both Lipitor and Crestor have been shown to effectively reduce the risk of heart disease over time. However, it is essential to consult with a healthcare professional to determine the most appropriate treatment plan for individual health needs.

Sources:

1. Baigent, C., Blackwell, L., Emberson, J., Holland, L. E., Reith, C., & Yusuf, S. (2005). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 11 randomised trials. The Lancet, 366(9481), 1267-1278. <https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67393-2/fulltext>
2. Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., ... & Theroux, P. (2004). Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine, 350(15), 1495-1504. <https://www.nejm.org/doi/full/10.1056/NEJMoa035600>
3. Nissen, S. E., & Wolski, K. (2007). Effect of rosuvastatin on progression of coronary atherosclerosis: the JUPITER trial. Journal of the American Medical Association, 297(9), 935-942. <https://jamanetwork.com/journals/jama/fullarticle/209932>
4. DrugPatentWatch.com. (n.d.). Lipitor (atorvastatin) Patents. <https://www.drugpatentwatch.com/patent/lipitor-atorvastatin/>
5. DrugPatentWatch.com. (n.d.). Crestor (rosuvastatin) Patents. <https://www.drugpatentwatch.com/patent/crestor-rosuvastatin/>